Burden of complications after giant cell tumor surgery. A single-center retrospective study of 192 cases

被引:5
作者
Barnaba, Anne [1 ]
Colas, Manon [1 ]
Larousserie, Frederique [1 ]
Babinet, Antoine [1 ]
Anract, Philippe [1 ]
Biau, David [1 ]
机构
[1] Hop Cochin, Serv Chirurg Orthoped, 27 Rue Faubourg St Jacques, F-75014 Paris, France
关键词
Giant cell tumor of bone; Bone tumor; Tumor recurrence; Bone curettage; LOCAL RECURRENCE; PATHOLOGICAL FRACTURE; LONG-BONE; CURETTAGE; CRYOSURGERY; CEMENT; RISK;
D O I
10.1016/j.otsr.2021.103047
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
Background: Surgical complications are frequent with giant cell tumor of bone; recurrence is the best known and most widely studies; other causes of failure have been less well investigated. We therefore performed a retrospective study to identify and assess the main reasons for surgical revision. Hypothesis: Recurrence is the main cause of surgical revision in giant cell tumor of bone, but other complications, such as mechanical issues or infection, are underestimated. Patients and methods: A single-center retrospective study included 192 patients (included from 2000 to 2016) undergoing first giant cell tumor of bone surgery in a bone tumor reference center. Surgery consisted in curettage for 152 patients (79%) and resection for 40 (21%). The 3 main reconstruction techniques were filling (136 patients; 71%), prosthesis (18 patients; 9%), and fusion (14 patients: 7%). Filling used cement in 9 cases (7%) and bone graft in 127 (93%). Cumulative incidence functions were calculated. Results: There were 171 revision procedures in 92 patients: 43 for mechanical reasons, 30 for infection, 86 for tumor recurrence, 12 for other causes. Cumulative incidence of revision at 10 years was 36% (95% CI: 27-44) for recurrence, 26% (95% CI: 17-36) for mechanical causes, and 13% (95% CI: 9-19) for infection, for overall cumulative incidence of revision of 61% (95% CI: 50-69). Discussion: Risk of all-cause surgical revision in giant cell tumor of bone was 61% at 10 years, with recurrence accounting for only half of cases. Level of evidence: IV.(c) 2021 Published by Elsevier Masson SAS.
引用
收藏
页数:7
相关论文
共 46 条
[1]   NEW LOOK AT STATISTICAL-MODEL IDENTIFICATION [J].
AKAIKE, H .
IEEE TRANSACTIONS ON AUTOMATIC CONTROL, 1974, AC19 (06) :716-723
[2]  
Algawahmed H., 2010, Sarcoma, V2010, P586090, DOI 10.1155/2010/586090
[3]  
[Anonymous], COORDONNES RCP SARCO
[4]   Giant cell tumor of bone: treatment and outcome of 214 cases [J].
Balke, Maurice ;
Schremper, Laura ;
Gebert, Carsten ;
Ahrens, Helmut ;
Streitbuerger, Arne ;
Koehler, Gabriele ;
Hardes, Jendrik ;
Gosheger, Georg .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2008, 134 (09) :969-978
[5]   Supplemental Bone Grafting in Giant Cell Tumor of the Extremity Reduces Nononcologic Complications [J].
Benevenia, Joseph ;
Rivero, Steven M. ;
Moore, Jeffrey ;
Ippolito, Joseph A. ;
Siegerman, Daniel A. ;
Beebe, Kathleen S. ;
Patterson, Francis R. .
CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, 2017, 475 (03) :776-783
[6]   Permutation tests for centre effect on survival endpoints with application in an acute myeloid leukaemia multicentre study [J].
Biard, L. ;
Porcher, R. ;
Resche-Rigon, M. .
STATISTICS IN MEDICINE, 2014, 33 (17) :3047-3057
[7]   Treatment of giant-cell tumors of long bones with curettage and bone-grafting [J].
Blackley, HR ;
Wunder, JS ;
Davis, AM ;
White, LM ;
Kandel, R ;
Bell, RS .
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 1999, 81A (06) :811-820
[8]   GIANT-CELL TUMOR OF BONE [J].
CAMPANACCI, M ;
BALDINI, N ;
BORIANI, S ;
SUDANESE, A .
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 1987, 69A (01) :106-114
[9]  
Chanchairujira Kullanuch, 2011, Journal of the Medical Association of Thailand, V94, P1230
[10]   Evaluation of Local Recurrence in Giant-Cell Tumor of Bone Treated by Neoadjuvant Denosumab [J].
Chinder, Pramod Shekarappa ;
Hindiskere, Suraj ;
Doddarangappa, Srinath ;
Pal, Utkarsh .
CLINICS IN ORTHOPEDIC SURGERY, 2019, 11 (03) :352-360